-
Product Insights
NewHemochromatosis – Drugs In Development, 2024
Empower your strategies with our Hemochromatosis – Drugs In Development, 2024 report and make more profitable business decisions. Hemochromatosis is an iron disorder in which the body simply retains too much iron. Symptoms include joint pain, abdominal pain, fatigue, weakness, diabetes, liver failure, and heart failure. Risk factors include family history, alcoholism, taking dietary supplements with iron or vitamin C, and history of diabetes, heart disease, or liver disease. The Hemochromatosis drugs in development market research report provide comprehensive information on...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NLG-207 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NLG-207 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NLG-207 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)...
-
Product Insights
NewRestless Legs Syndrome – Drugs In Development, 2024
Empower your strategies with our Restless Legs Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a disorder of the part of the nervous system that affects the legs and causes an urge to move them. Symptoms include itching, pain, a creepy-crawly feeling, and cramping in the calf or leg muscles. A predisposing factor is age. Treatment includes muscle relaxants, sleep medications, and narcotic medications. The...
-
Product Insights
NewHyperparathyroidism – Drugs In Development, 2024
Empower your strategies with our Hyperparathyroidism – Drugs In Development, 2024 report and make more profitable business decisions. Hyperparathyroidism is an increase in parathyroid hormone (PTH) levels in the blood. In hyperparathyroidism, one or more of parathyroid glands becomes overactive and makes excess PTH. This could be due to a tumor, gland enlargement, or other structural problems of the parathyroid glands.Symptoms of hyperparathyroidism are caused by inappropriately normal or elevated blood calcium leaving the bones and flowing into the blood stream...
-
Product Insights
NewHeart Valve Disease – Drugs In Development, 2024
Empower your strategies with our Heart Valve Disease – Drugs In Development, 2024 report and make more profitable business decisions. Heart valve diseases are problems affecting one or more of the four valves in the heart, where the heart valve or valves do not open or close properly with every heartbeat, causing disruption of blood flow. Stenosis, regurgitation, and atresia are a few types of heart valve diseases. Signs and symptoms can range from mild to severe, including chest pain, irregular...
-
Product Insights
NewSecondary Hyperparathyroidism – Drugs In Development, 2024
Empower your strategies with our Secondary Hyperparathyroidism – Drugs In Development, 2024 report and make more profitable business decisions. Secondary hyperparathyroidism is occurs when the parathyroid glands in the neck produce too much parathyroid hormone (PTH) because calcium levels are too low. Symptoms include bone deformities, broken bones, swollen joints, and chronic kidney failure. Treatment includes calcimimetic and hormone replacement therapy. The Secondary Hyperparathyroidism drugs in development market research report provide comprehensive information on the therapeutics under development for Secondary Hyperparathyroidism,...
-
Product Insights
NewAortic Valve Diseases – Drugs In Development, 2024
Empower your strategies with our Aortic Valve Diseases – Drugs In Development, 2024 report and make more profitable business decisions. Aortic Valve Disease (AVD) is a type of valve disease where hearts aortic valve does not work properly. Aortic valve controls the flow of blood from heart to all the body parts. When there is a damage to the aortic valve blood flow is affected. The 2 main aortic valve diseases are aortic stenosis and aortic regurgitation. In aortic stenosis blood...
-
Product Insights
NewAortic Valve Stenosis – Drugs In Development, 2024
Empower your strategies with our Aortic Valve Stenosis – Drugs In Development, 2024 report and make more profitable business decisions. Aortic valve stenosis (AVS) is caused by narrowing of the heart's aortic valve opening. The valve between the lower left heart chamber and the body's main artery (aorta) is narrowed and doesn't open fully, which obstructs blood flow from the heart into the aorta and onward to the rest of the body. AVS can range from mild to severe. Signs and...
-
Product Insights
NewChemotherapy Induced Anemia – Drugs In Development, 2024
Empower your strategies with our Chemotherapy Induced Anemia – Drugs In Development, 2024 report and make more profitable business decisions. Chemotherapy-induced anemia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain, dizziness, cognitive impairment, loss of sexual desire, inability to perform daily functions, and/or depression associated with anemia. The predisposing factors include age, co-morbidities, and the time course of...
-
Product Insights
NewThalassemia – Drugs In Development, 2024
Empower your strategies with our Thalassemia – Drugs In Development, 2024 report and make more profitable business decisions. Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite, and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow transplant. The Thalassemia drugs in development market research report provide comprehensive information on the therapeutics under development for...